📌 𝐅𝐨𝐥𝐥𝐨𝐰 𝐨𝐧 𝐈𝐧𝐬𝐭𝐚𝐠𝐫𝐚𝐦:- https://www.instagram.com/drgbhanuprakash
📌𝗝𝗼𝗶𝗻 𝗢𝘂𝗿 𝗧𝗲𝗹𝗲𝗴𝗿𝗮𝗺 𝗖𝗵𝗮𝗻𝗻𝗲𝗹 𝗛𝗲𝗿𝗲:- https://t.me/bhanuprakashdr
📌𝗦𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝗧𝗼 𝗠𝘆 𝗠𝗮𝗶𝗹𝗶𝗻𝗴 𝗟𝗶𝘀𝘁:- https://linktr.ee/DrGBhanuprakash

WHAT ARE DISEASE-MODIFYING ANTIRHEUMATIC DRUGS?

DMARDs work to suppress the body’s overactive immune and/or inflammatory systems. They take effect over weeks or months and are not designed to provide immediate relief of symptoms.

Other medicines, such as pain relievers, nonsteroidal anti-inflammatory drugs (eg, ibuprofen or naproxen), and, sometimes, prednisone, are given to provide faster relief of ongoing symptoms. DMARDs are often used in combination with these medications to reduce the total amount of medication needed and to prevent damage to joints.

DISEASE-MODIFYING ANTIRHEUMATIC DRUGS — The choice of DMARD depends on a number of factors, including the stage and severity of the joint condition, the balance between possible side effects and expected benefits, and patient preference. Before treatment begins, the patient and clinician should discuss the benefits and risks of each type of therapy, including possible side effects and toxicities, dosing schedule, monitoring frequency, and expected results. Certain screening tests, including blood tests for past exposure to certain infections, may be needed before starting some of these medications.

In some cases, one DMARD is used. In others, more than one medication may be recommended. Sometimes a patient must try different medicines or combinations to find one that works best and that has the fewest side effects. A patient who does not respond completely to a single DMARD may be given a combination of DMARDs, such as methotrexate plus another medication.

The most common DMARDs are methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide. Less frequently used medications include gold salts, azathioprine, and cyclosporine.
Video Rating: / 5

Disease modifying anti-rheumatic drugs (DMARDs); what you need to know before taking them. Talk to your healthcare team for more information.

Please find the iBook available for download here: https://itunes.apple.com/us/book/rheum-medi-info/id1123774842?ls=1&mt=11

Project credit
A Master’s Research Project submitted in conformity with the requirements for the degree of Master of Science in Biomedical Communications (MScBMC).
Offered through the Institute of Medical Sciences, Faculty of Medicine, University of Toronto in collaboration with Biomedical Communications, Department of Biology, University of Toronto Mississauga.

Copyright 2016 Marina Spyridis.

Committee members
Shelley Wall, AOCAD, MA, MScBMC, PhD, CMI
Assistant Professor, Biomedical Communications
Department of Biology
University of Toronto Mississauga

Shirley Tse, MD, FRCPC
Associate Professor, Department of Paediatrics
Faculty of Medicine
University of Toronto

Any material in this iBook may not be manipulated, reproduced or distributed without permission.

Comments: advertising treatments, of a negative nature, or unrelated to this video content will be removed. This is meant as an introductory educational tool for children, young adults and adults.

Share this page: